Journal article
Effect of Denosumab on Bone Health in Adult Patients with Duchenne/Becker Muscular Dystrophy: A Report of 2 Cases
JBJS case connector, Vol.12(1), e21.00664
03/16/2022
DOI: 10.2106/JBJS.CC.21.00664
PMID: 35294424
Abstract
Duchenne/Becker muscular dystrophy (DMD/BeMD) is caused by a loss of dystrophin leading to muscular weakness. Glucocorticoids are used to delay loss of muscle strength but frequently result in osteoporosis and fractures. Bisphosphonates are the drug of choice, and there are limited data on the efficacy of denosumab. We describe 2 patients who were treated with denosumab and had stable to improved bone density with no side effects.
Denosumab can be considered for the treatment of osteoporosis in adults with DMD/BeMD, especially when the response to bisphosphonates is not satisfactory.
Details
- Title: Subtitle
- Effect of Denosumab on Bone Health in Adult Patients with Duchenne/Becker Muscular Dystrophy: A Report of 2 Cases
- Creators
- Chermaine Hung - University of IowaKatherine D Mathews - University of IowaAmal Shibli-Rahhal - University of Iowa
- Resource Type
- Journal article
- Publication Details
- JBJS case connector, Vol.12(1), e21.00664
- DOI
- 10.2106/JBJS.CC.21.00664
- PMID
- 35294424
- NLM abbreviation
- JBJS Case Connect
- eISSN
- 2160-3251
- Language
- English
- Date published
- 03/16/2022
- Academic Unit
- Neurology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Neurology (Pediatrics); Medicine Administration; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984229186402771
Metrics
10 Record Views